IGM Biosciences (NASDAQ:IGMS) Shares Gap Up to $18.76
IGM Biosciences (NASDAQ:IGMS) Shares Gap Up to $18.76
Shares of IGM Biosciences, Inc. (NASDAQ:IGMS – Get Rating) gapped up before the market opened on Tuesday . The stock had previously closed at $18.76, but opened at $20.16. IGM Biosciences shares last traded at $20.10, with a volume of 498 shares trading hands.
周二开盘前，IGM Biosciences，Inc.(纳斯达克代码：IGMS-GET Rating)的股价大幅上涨。该股此前收盘报18.76美元，开盘报20.16美元。IGM Biosciences的股票最新报20.10美元，成交量为498股。
Analysts Set New Price Targets
分析师设定新的价格目标
IGMS has been the topic of several research analyst reports. Robert W. Baird decreased their price objective on shares of IGM Biosciences from $46.00 to $31.00 and set an "outperform" rating on the stock in a research note on Wednesday, June 1st. Bank of America began coverage on shares of IGM Biosciences in a report on Monday, August 29th. They set a "buy" rating and a $34.00 price objective on the stock. Guggenheim reduced their target price on shares of IGM Biosciences to $40.00 in a research report on Monday, August 15th. Finally, Truist Financial dropped their price objective on shares of IGM Biosciences from $74.00 to $37.00 and set a "buy" rating for the company in a research report on Tuesday, August 23rd. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $53.00.
IGMS一直是几份研究分析师报告的主题。罗伯特·W·贝尔德在6月1日星期三的一份研究报告中将IGM Biosciences的股票目标价从46.00美元下调至31.00美元，并对该股设定了“跑赢大盘”的评级。美国银行在8月29日星期一的一份报告中开始报道IGM Biosciences的股票。他们为该股设定了“买入”评级和34.00美元的目标价。古根海姆在8月15日星期一的一份研究报告中将IGM Biosciences的股票目标价下调至40.00美元。最后，Truist Financial在8月23日(星期二)的一份研究报告中将IGM Biosciences的股票目标价从74.00美元下调至37.00美元，并为该公司设定了“买入”评级。两名投资分析师对该股的评级为持有，七名分析师对该公司的评级为买入。根据MarketBeat.com的数据，该公司目前的平均评级为“中等买入”，平均目标价为53.00美元。
IGM Biosciences Stock Performance
IGM Bioscions股票表现
The firm's 50-day simple moving average is $20.28 and its 200 day simple moving average is $18.81. The company has a market cap of $839.12 million, a P/E ratio of -3.54 and a beta of -0.32.
该公司的50日简单移动均线切入位为20.28美元，200日简单移动均线切入位为18.81美元。该公司市值为8.3912亿美元，市盈率为-3.54，贝塔系数为-0.32。
Insider Activity at IGM Biosciences
IGM生物科学公司的内部活动
In related news, insider Bruce Keyt sold 8,700 shares of the business's stock in a transaction that occurred on Friday, August 19th. The shares were sold at an average price of $22.82, for a total transaction of $198,534.00. Following the completion of the transaction, the insider now owns 39,489 shares in the company, valued at $901,138.98. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders have sold 30,000 shares of company stock worth $622,107 in the last ninety days. Company insiders own 55.96% of the company's stock.
在相关新闻中，内部人士Bruce KEYT在8月19日星期五的一笔交易中出售了8700股该公司的股票。这些股票以22.82美元的平均价格出售，总成交金额为198,534.00美元。交易完成后，这位内部人士现在拥有该公司39,489股，价值901,138.98美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的，该文件可以通过美国证券交易委员会网站。在过去的90天里，内部人士卖出了30,000股公司股票，价值622,107美元。公司内部人士持有该公司55.96%的股份。
Hedge Funds Weigh In On IGM Biosciences
对冲基金参与IGM生物科学
A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Point72 Hong Kong Ltd bought a new stake in shares of IGM Biosciences in the 4th quarter valued at $34,000. Amalgamated Bank bought a new stake in shares of IGM Biosciences in the first quarter worth about $36,000. Captrust Financial Advisors acquired a new stake in shares of IGM Biosciences during the second quarter worth about $50,000. US Bancorp DE lifted its holdings in shares of IGM Biosciences by 608.4% during the 1st quarter. US Bancorp DE now owns 2,437 shares of the company's stock valued at $65,000 after purchasing an additional 2,093 shares in the last quarter. Finally, American International Group Inc. grew its position in shares of IGM Biosciences by 15.0% in the 2nd quarter. American International Group Inc. now owns 4,684 shares of the company's stock valued at $84,000 after purchasing an additional 612 shares during the period. 41.20% of the stock is owned by institutional investors.
一些对冲基金和其他机构投资者最近对他们在该公司的头寸进行了调整。Point72 Hong Kong Ltd在第四季度购买了IGM Biosciences的新股，价值34,000美元。合并银行在第一季度购买了IGM Biosciences价值约3.6万美元的新股。CapTrust Financial Advisors在第二季度收购了IGM Biosciences价值约5万美元的新股。美国Bancorp DE在第一季度增持了IGM Biosciences的股票，增幅为608.4%。US Bancorp DE现在拥有2437股该公司股票，价值6.5万美元，此前在上个季度又购买了2093股。最后，美国国际集团(AIG)在第二季度增持了IGM Biosciences股票15.0%。美国国际集团(American International Group Inc.)在此期间又购买了612股，目前持有该公司4,684股股票，价值8.4万美元。41.20%的股份由机构投资者持有。
About IGM Biosciences
关于IGM生物科学
(Get Rating)
(获取评级)
IGM Biosciences, Inc, a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL).
IGM生物科学公司是一家生物技术公司，开发用于治疗癌症、传染病、自身免疫性疾病和炎症性疾病的免疫球蛋白M(IgM)抗体。该公司的主要候选产品是IGM-2323，这是一种双特异性IgM抗体，正处于第二阶段临床试验，用于治疗复发/难治性B细胞非霍奇金淋巴瘤(NHL)患者。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on IGM Biosciences (IGMS)
- Build A Better Tech Portfolio With Jabil Inc.
- Autodesk Is A Mature Company Still Acting Like A Growth Stock
- Is There Value In These Growth Stocks?
- MarketBeat Podcast, 3 Stocks to Watch Newmont Mining, Walmart, AMC
- MO Money: Why Altria Group Stock is Rallying
- 免费获取StockNews.com关于IGM生物科学的研究报告(IGMS)
- 与捷普公司一起打造更好的技术产品组合。
- 欧特克是一家成熟的公司，仍是一只成长型股票
- 这些成长型股票有价值吗？
- MarketBeat Podcast，3只股票关注纽蒙特矿业、沃尔玛、AMC
- Mo Money：奥驰亚集团股价为何上涨
Receive News & Ratings for IGM Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IGM Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
接受IGM《生物科学日报》的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对IGM Biosciences和相关公司的最新新闻和分析师评级的每日简明摘要。